Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on October 16, 2006.
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 192
- Registration Number
- NCT02072096
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇺🇸Carolina Health Specialists, Myrtle Beach, South Carolina, United States
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
- Conditions
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 249
- Registration Number
- NCT02060383
- Locations
- 🇺🇸
LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States
🇺🇸Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States
🇺🇸East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States
Use of Sitagliptin to Decrease Microalbuminuria
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 142
- Registration Number
- NCT02048904
- Locations
- 🇺🇸
University of Missouri-Columbia: Diabetes Center, Columbia, Missouri, United States
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
- Conditions
- Interventions
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 90
- Registration Number
- NCT02043054
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Diabetes Research Centre, Leicester, Leicestershire, United Kingdom
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 464
- Registration Number
- NCT02036515
Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 1
- Registration Number
- NCT02015910
- Locations
- 🇺🇸
Medstar Georgetown University Hospital, Washington, District of Columbia, United States
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 368
- Registration Number
- NCT02008682
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1326
- Registration Number
- NCT01999218
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- University College Dublin
- Target Recruit Count
- 20
- Registration Number
- NCT01991197
- Locations
- 🇮🇪
UCD Clinical Research Centre, St Vincent's University Hospital,, Dublin 4, Ireland
🇮🇪The Adelaide and Meath Hospital, Dublin 24, Ireland
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01984606
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.